18 documents

Read All
21:12 , May 9, 2018 |  BC Innovations  |  Translation in Brief

The fate of NK cells

New research is elucidating the relationship between CAR-transfected NK cells’ differentiation states and their cancer-killing potential -- knowledge that Fate Therapeutics Inc. (NASDAQ:FATE) is leveraging for its own cell therapies. In a study published in Cancer...
Read More
23:05 , Jan 18, 2018 |  BC Innovations  |  Translation in Brief

A notch for tankyrase

New York University School of Medicine researchers have identified a multitude of tankyrase targets, including factors in the Notch and Wnt/β-catenin pathways, that offer new opportunities for tankyrase inhibitors in cancer. In a Nature Communications study...
Read More
22:27 , Mar 16, 2017 |  BC Innovations  |  Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...
Read More
19:06 , Jan 6, 2017 |  BioCentury  |  Emerging Company Profile

Gobbling globulins

Syntimmune Inc. is targeting a receptor that mediates the life span and activity of immunoglobulin G to control autoimmune disease more precisely and potentially more safely than broadly acting agents. The company aims to differentiate...
Read More
07:00 , Aug 17, 2015 |  BioCentury  |  Finance

Medigene remade

Within 18 months, Medigene AG has used a small acquisition to gain a new, predominantly institutional shareholder base that has infused the German company with enough cash to pursue three platforms in parallel. Management...
Read More
08:00 , Nov 13, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Kai-Jye Lou and Stephen Parmley, Senior Writers, and Mark Zipkin, Staff Writer  Tankyrase translation   With a few pharmas entering the search for tankyrase inhibitors for cancer, Merck KGaA is hedging its bets by joining forces with The...
Read More
07:00 , Sep 12, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) Methyltransferase like 21A (METTL21A); heat shock 70 kDa protein 8...
Read More
07:00 , Aug 1, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Kallikrein-related peptidase 4 (KLK4) Cell culture and mouse studies suggest...
Read More
07:00 , Apr 18, 2013 |  BC Innovations  |  Cover Story

Targeting tankyrase

Researchers from the University of Oslo and Roche's Genentech Inc. unit have developed several selective inhibitors of tankyrases TNKS and TNKS2, two druggable targets in the otherwise hard-to-hit WNT pathway.1,2 The University team's lead compound...
Read More
08:00 , Feb 27, 2012 |  BC Week In Review  |  Company News

Oxford Gene, University of Oslo deal

Inven2, the technology transfer arm of the university, granted Oxford Gene exclusive rights to develop and commercialize 12 colorectal cancer tissue biomarkers. Oxford Gene said the biomarkers had 93% sensitivity and 90% specificity using tissue...
Read More